Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Rectal Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Intestinal Diseases

Rectal Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Trastuzumab

Tislelizumab

Immunomodulating Agents

Oxaliplatin

Antineoplastic Agents, Immunological

CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative):

Cycle 1 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy Cycle: Day 1 through Day 21

CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive ):

Cycle 1 up to Cycle 3 CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) Cycle: Day 1 through Day 21

Rectal cancer:

Cycle 1:25 Gy/5 fractions (Day 1 through Day 7) Cycle 2 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy(Day 1 through Day 21)

q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle

Terelizumab (aka Tislelizumab)

Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days

CapeOx

q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle

Radiotherapy

wang bin

wang lei

immunotherapy，gastric cancer，rectal cancer，biomark

To investigate the effect of Terelizumab (aka Tislelizumab) combined with XELOX in Neoadjuvant Therapy for gastrointestinal tumors.

To explore new biomarkers that can predict the efficacy of combined immunotherapy, and to establish a clinical efficacy prediction model by means of bioinformatics to prospectively judge the efficacy and guide the follow-up individualized and accurate treatment.

Gastric cancer:CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative)（n=80） Gastric cancer:CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive )（n=20） Rectal cancer:Radiotherapy with CapeOx+ Terelizumab (aka Tislelizumab)（n=100）

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Clinical Application of Efficacy Prediction Model Based on Epigenetics Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric cancer and rectal cancer：The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions.

EORTC Quality of Life Questionnaire - Gastric Cancer Module:to be used in conjunction with the EORTC QLQ-C30 to assess health-related quality of life in gastric cancer.

EORTC Quality of Life Questionnaire - Colorectal Cancer Module:to be used in conjunction with the EORTC QLQ-C30 to assess quality of life in patients with colorectal cancer

Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging

Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor

It is defined as residual tumors less than 10% after neoadjuvant immunotherapy and(or) chemotherapy

Time from study entry to death from any cause.

Time from study entry to disease recurrence or patient death due to disease progression

Rate of microscopically margin-negative resection

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	NCT05515796	Immunotherapy Gastric Cancer Rectal Cancer Chemotherapy Ef... Radiotherapy	Terelizumab (ak... CapeOx Trastuzumab Radiotherapy	19 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	NCT05515796	Immunotherapy Gastric Cancer Rectal Cancer Chemotherapy Ef... Radiotherapy	Terelizumab (ak... CapeOx Trastuzumab Radiotherapy	19 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Spots Global Cancer Trial Database for terelizumab (aka tislelizumab)